Yestar Healthcare Holdings Company Limited (“Yestar Health”; 02393.HK) has issued a profit warning, stating that preliminary unaudited figures point to a consolidated net loss of no less than RMB65.00 million for the financial year ended 31 December 2025 (FY2025). This compares with a net profit of RMB903.50 million in FY2024.

Management attributes the expected swing to two main factors:

1. FY2024 booked a one-off gain of approximately RMB1.08 billion from the discounted redemption of senior notes due 2026, a gain that will not recur in FY2025. 2. Impairment losses on non-financial assets are anticipated for FY2025.

The audited FY2025 results are scheduled for release on 27 March 2026. The board cautions investors that the current figures are based on internal management accounts and remain subject to further review and potential adjustment. Shareholders and potential investors are advised to act prudently when dealing in the company’s shares.